Synergy Pharmaceuticals (SGYP) Shares are Up 11.77%

Synergy Pharmaceuticals (SGYP) : Traders are bullish on Synergy Pharmaceuticals (SGYP) as it has outperformed the S&P 500 by a wide margin of 7.99% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 11.29%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 11.77% in the last 1 week, and is up 10.68% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

Synergy Pharmaceuticals (NASDAQ:SGYP): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $4.25 and $4.21 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $4.62. The buying momentum continued till the end and the stock did not give up its gains. It closed at $4.56, notching a gain of 8.06% for the day. The total traded volume was 2,949,559 . The stock had closed at $4.22 on the previous day.

The stock has recorded a 20-day Moving Average of 14.37% and the 50-Day Moving Average is 18.34%. Synergy Pharmaceuticals, Inc. is up 61.7% in the last 3-month period. Year-to-Date the stock performance stands at -19.58%.

Synergy Pharmaceuticals (SGYP) : 2 Wall Street analysts covering Synergy Pharmaceuticals (SGYP) believe that the average level the stock could reach for the short term is $10.75. The maximum price target given is $15 and the minimum target for short term is around $7, hence the standard deviation is calculated at $6.01.


Synergy Pharmaceuticals Inc. (Synergy) is a biopharmaceutical company focused on the development of drugs to treat gastrointestinal (GI), disorders and diseases. The Companys platform technology is based on the naturally occurring human GI peptide, uroguanylin, a regulator of normal GI physiology. The Companys products include plecanatide, SP-333 and FV-100. The Companys lead product is plecanatide, a guanylate cyclase C (GC-C), receptor agonist, designed to treat GI disorders, primarily chronic idiopathic constipation (CIC), and constipation predominant irritable bowel syndrome (IBS-C). The Company is developing a second-generation GC-C receptor agonist, SP-333, for the treatment of opioid induced constipation (OIC), and for inflammatory bowel disease (IBD). FV-100 is an orally available nucleoside analog. The Companys subsidiaries include Synergy Advanced Pharmaceuticals, Inc., IgX, Ltd and ContraVir Pharmaceuticals, Inc.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.